Trial | Line of treatment | Number of patients | Regimen | Asian population | mPFS (mo), ET+CDKi vs. ET |
---|---|---|---|---|---|
MONALEESA-2 | 1st | 668 | Letrozole ± ribociclib | 7.6% |  |
MONALEESA-7 | 1st | 672 | Endocrine ± ribociclib | 29.5% | 30.4 vs. 11.0 |
MONARCH-3 | 1st | 493 | NSAI ± abemaciclib | 30.0% |  |
PALOMA-2 | 1st | 666 | Letrozole ± palbociclib | 14.2% | 25.7 vs. 13.9 |
MONALEESA-3 | 1st and 2nd | 726 | Fulvestrant ± ribociclib | 8.7% | NR vs. 12.7a |
MONARCH 2 | 2nd | 669 | Fulvestrant ± abemaciclib | 32.0% | 22.8 vs. .11.6 |
PALOMA-3 | 2nd or later | 521 | Fulvestrant ± palbociclib | 21.0% | NR vs. 5.8 |